JAZZ PHARMACEUTICALS INC Form 8-K August 23, 2010

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

August 20, 2010

Date of Report (Date of earliest event reported)

JAZZ PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

Delaware 001-33500 05-0563787

(State or Other Jurisdiction	(Commission	(IRS Employer
of Incorporation)	File No.) 180 Porter Drive, Palo Alto, California 94304	Identification No.)
(Address of principal executive offices, including zip code)		
	(650) 496-3777	
(Registrant s telephone number, including area code)		
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any o the following provisions:		
" Written communications pursuant to Rule 4	425 under the Securities Act (17 CFR 230.425)	
" Soliciting material pursuant to Rule 14a-12	under the Exchange Act (17 CFR 240.14a-12)	

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On August 20, 2010, Jazz Pharmaceuticals, Inc. issued a press release titled Jazz Pharmaceuticals Provides Update on FDA Advisory Committee Meeting For JZP-6 (Sodium Oxybate) in Fibromyalgia. A copy of the press release is furnished as Exhibit 99.1 to this report.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Number Description

99.1 Press Release dated August 20, 2010

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

JAZZ PHARMACEUTICALS, INC.

By: /s/ Bruce C. Cozadd

Bruce C. Cozadd Chairman and Chief Executive Officer

Date: August 23, 2010

EXHIBIT INDEX

Exhibit

Number Description

99.1 Press Release dated August 20, 2010